Anca Cerghizan

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 3K citations · Full text

Medicine, Endocrinology, Pharmacology +14

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 629 citations · Full text

Medicine, Endocrinology, Nephrology +15

Social jetlag, sleep‐related parameters, and glycemic control in adults with type 1 diabetes: Results of a cross‐sectional study

Adriana Rusu, Dana Mihaela Ciobanu, Cornelia Bala et al. · Journal of Diabetes · 2018 · 38 citations

Medicine, Endocrinology, Internal Medicine +17

Real-world evidence on the use of a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) in people with suboptimally controlled type 2 diabetes in Romania: a prospective cohort study (STAR.Ro)

Cornelia Bala, Anca Cerghizan, Bogdan-Mircea Mihai et al. · BMJ Open · 2022 · 22 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Sleep quality and sleep duration, but not circadian parameters are associated with decreased insulin sensitivity in Type 1 diabetes

Adriana Rusu, Cornelia Bala, Dana Mihaela Ciobanu et al. · Chronobiology International · 2019 · 16 citations

Medicine, Endocrinology, Internal Medicine +17